Objective: To assess whether supplementation with hCG throughout the secretory phase of hormonally modulated cycles of frozen-thawed embryos might positively affect the outcome of such cycles.
Design: Prospective, randomized controlled trial.
Setting: University teaching hospital.
Patient(s): Patients undergoing frozen-thawed embryo transfer cycles.
Intervention(s): Patients were randomly divided into two groups by the last digit of their identification number. Group A received our standard protocol for endometrial preparation, whereas group B patients were given an additional 250 microg of recombinant hCG on day of P initiation, the day of embryo transfer, and 6 days later. Throughout the cycle, and to compare between the groups, serial ultrasound examinations and hormonal tests of E(2) and P serum levels were obtained.
Main outcome measure(s): Implantation and clinical pregnancy rates (PR).
Result(s): One hundred sixty-five patients were enrolled in this study, 78 in the control group and 87 in the hCG-treated group. Progesterone levels and endometrial thickness were similar throughout the cycle in both groups. The E(2) level was significantly higher in group B on the day of embryo transfer and 6 days later. The PRs did not differ between the two groups (28.2% and 32.2% for groups A and B, respectively). Similarly, the implantation rates were comparable between the groups (12.7% and 14.9%, respectively).
Conclusion(s): No advantage was found concerning PR and implantation rate by supplementing the secretory phase with hCG in patients undergoing transfer of frozen-thawed embryo in hormonally modulated cycles.
Copyright 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.